ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
ORIC Pharmaceuticals (ORIC) partnered with Cancer Research UK to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development. Cancer Research UK will fund and execute early clinical trials, while ORIC retains an option to reacquire rights post-Phase 1/2 data. ORIC-259 targets CIP2A, a protein linked to cancer progression, with promising preclinical data showing antitumor activity in HRD cancers.
How this was made
The 30-second read
Why it matters
The agreement de‑risks the pre‑clinical program, potentially improving ORIC's valuation and attracting further capital.
Market read
A small‑cap biotech receives non‑dilutive funding for a novel therapy, offering a modest positive catalyst for the stock.
What to watch
Milestone payments and royalties could dilute future upside if the program succeeds.
Background
ORIC is a clinical‑stage oncology company with a pipeline that includes PRC2 and EGFR inhibitors. The new ORIC-259 partnership adds a novel CIP2A‑targeted approach.
Ticker impact
ORIC Pharmaceuticals announced a funding and development partnership with Cancer Research UK for its ORIC-259 program, a first‑in‑class CIP2A‑targeted therapy.
likely modest upside as investors price in reduced development risk and potential future milestones.
Funding from a reputable nonprofit and exclusive rights option suggest a favorable near‑term catalyst, though clinical outcomes remain uncertain.
Market effects
Highlights growing interest in mRNA‑degrader platforms within oncology biotech.
Positive signal for US biotech investors; limited broader market effect.
Shows collaboration between US biotech and UK research institutions, modest global relevance.
Counterpoint
Funding may be limited to early phases; without later-stage financing the program could stall.
Key entities
- companyORIC Pharmaceuticals, Inc.
US‑listed biotech developing oncology therapeutics (Nasdaq: ORIC).
- institutionCancer Research UK
UK nonprofit funder providing full development support for ORIC-259.
